Peptides reactive with two neutralizing monoclonal antibodies raised against intact foot-and-mouth disease virus A10 were identified with the aid of all overlapping (hexa)peptides of the outer structural viral protein VP 1 and located on the viral surface.
INTRODUCTION
Interest in the application of synthetic peptides has increased considerably during the past few years. Areas of interest range from oncogene products, peptide hormones, brain-specific proteins and bacterial toxins to peptide vaccines (Tanaka et al., 1985; Sutcliffe et al., 1983; Houghten et al., 1984; Dardenne et al., 1985; Lerner, 1982) . Because peptide vaccines have a number of advantages compared to classical vaccines a considerable effort is being put into their development. Success is dependent upon the ability to predict and use the correct peptide. A limitation of this general approach is the problem of deciding which region of a protein it would be most appropriate to synthesize, and although there are a number of methods which may be applied to a primary sequence, the data obtained are of limited value (Meloen & Banding, 1986 a) . The most useful peptides have been obtained with the aid of data applicable to foot-andmouth disease virus (FMDV) only (Bittle et al., 1982; Pfaffet al., 1982; Di Marchi et al., 1986) . This probably explains why success with peptide vaccines has been limited.
While a considerable amount of information is available on antigenic and/or immunogenic peptides (Atassi, 1978; Atassi & Kurisaki 1984; Bixter et al., 1984) , very little is known about the precise structure of epitopes with respect to the total number of amino acids involved and the amino acids contributing to antibody binding. So far only one antibody-antigen structure has been resolved at the level of 0.26 nm by crystallographic methods (Amit et al., 1986) .
To assess which peptides in a given primary sequence are antigenic we developed a rapid method that assesses the antigenicity of peptides in a systematic fashion. This method is now known as PEPSCAN (Geysen et al., 1984 (Geysen et al., , 1985 . It allows the rapid testing of all overlapping peptides of any given protein with polyclonal or monoclonal antibodies. Using similar methods it is further possible to learn which amino acids of antigenic peptides are important for recognition by antibodies.
In this report we present data obtained with two neutralizing monoclonal antibodies (MAbs) and all overlapping (hexa)peptides of the structural protein VP 1 of FMDV type A 10. Reactive peptides were further characterized with respect to amino acids that do or do not contribute to 0000-7282 © 1987 SGM their antigenicity. The results suggest the feasibility of considerable improvement of the antigenicity of most peptides studied so far. It is speculated that this may lead to a new generation of more active peptide vaccines.
METHODS

PEPSCAN.
Overlapping peptides of VP1 of FMDV type A10 were synthesized and tested as described previously (Geysen et al., 1984 (Geysen et al., , 1985 for the determination of the reactivity patterns of antisera. In short, scanning for antibody-reactive peptides required the synthesis of every overlapping peptide in the relevant protein sequence. For example, in the case of a hexapeptide scan, a protein of n residues can be read as (n -5) overlapping hexapeptides, in which peptide 1 consists of residues l to 6, peptide 2 of residues 2 to 7, and so on. The amino acid sequences were derived from the nucleotide sequence of FMDV type A 10 (Boothroyd et al., 1982) . The peptides still coupled to the solid supports were then tested against the appropriate sera in a normal ELISA. Absorbance values were plotted against the position of the N-terminal amino acid of the peptide in the total sequence.
In a replacement set, peptides are synthesized in which the amino acids for each residue position in the parent sequence are substituted one at a time by the other 19 natural amino acids, keeping the rest of the sequence the same. For example, a replacement set based on a parent sequence of six residues long requires the synthesis of 120 peptides including six copies of the parent sequence as controls.
Peptide synthesis. Peptides were synthesized in bulk according to the Merrifield solid phase method (Erickson & Merrifield, 1976) . For MAb 11, DLGSIAA(C), GDLGSIA(K) and K1NSLS(C) were prepared (amino acids in parentheses are those added to facilitate linking to the carrier protein). For MAb 18, LVRMKRA(C), VRMKRA(C), YKQKIIAP, (C)YKQKIIAP, (C)RYKQKIIAP and (C)RYKQKIIAPAKQ were prepared.
Preparation of antibodies. Monoclonal antibodies were prepared against purified FMDV type A10 by methods similar to those described (Meloen el al., 1983) .
Antisera against peptides were prepared in rabbits as described elsewhere (Geysen et al., 1985; Bittle et al., 1982) . In short, the peptides were coupled to keyhole limpet haemocyanin (KLH) as a protein carrier, either with glutaraldehyde (GDA) through the lysine or with N-maleimidobenzoyl-N-hydroxysuccinimide (MBS) through the cysteine of the peptide. One mg of peptide coupled to 1 mg of KLH emulsified in complete Freund's adjuvant was used for the single vaccination.
Serological tests. The microneutralization (MNT) test, radioimmunoassay (RIA) and ELISA were essentially those applied previously (Meloen & Briaire, 1980) . [3sS]Methionine-labelled virus particles, trypsin-treated virus particles and 12S viral subunits were used; isolated VP1 was prepared as described by Meloen & Briaire (1980) . When VP1 was used the ELISA plates were coated with isolated VP1 in the presence of 0.01% SDS. The antipeptide activity in anti-peptide sera was measured by an indirect ELISA in which the peptide was coupled to the solid phase (Surer, 1982; Shapira et al., 1984) .
Competition experiments. Competition experiments were done using microtitre plates coated with purified virus. In a preliminary titration the MAb dilution that gave 90% of the maximal absorbance was determined. Appropriately diluted antibody was added to virus-coated plates containing increasing amounts of competing antigen (peptide or purified virus). After incubation overnight at 4 °C the amount of antibody bound to the viruscoated surface was determined with anti-mouse conjugate as in a normal ELISA (Meloen et al., 1983) .
Location of reactive peptides on the virus structure. A wire model of the C-alpha backbone of the rhinovirus 14 structural proteins (Rossmann et al., 1985) was made with the aid of the coordinates of the C-alpha atoms provided by Dr M. G. Rossmann. With the alignment of all known primary sequences of the picornaviruses (A. Palmenberg, personal communication) the reactive peptides were located.
RESULTS
Location of peptides
Characteristics of the two neutralizing MAbs are given in Table 1 . Their reactivity with all overlapping hexapeptides of VP1 of FMDV type A10 is shown in Fig. 1 .
To learn about the antigenicity of peptides in general we studied the reactivities of MAb 11 and MAb 18, by producing the PEPSCANs of all overlapping three, four and five amino acid long peptides of VP1 (not shown).
MAb 18 reacted strongly with the three amino acids VRM starting at position 176 (also, but less strongly, with peptide VRH at 80). Furthermore it reacted with QKI at 202. In the four amino acid PEPSCAN the peptides reacted only weakly with MAb 18. In the five amino acid PEPSCAN it reacted markedly with VRMKR at 176 and with QKIIA at 202 but also to some 
IgG2 3.6 0.6 --6.1 --5.2 4.8 5.5 6.1 10 -4 * FMDV types A10, OI-BFS and C1 were used. 1" 140S is whole virus, 12S is subviral protein particle, 140S tryp is trypsin-treated whole virus, $ Serum titres are expressed as -log10 endpoint dilution. § In MNT, result was <0.3 and considered negative; in RIA, result was < 1.0; in ELISA, result was <2.0.
extent with DRYKQ at 198. In the six amino acid scan, LVRMKR at 175,VRMKRA at 176 and QKIIAP at 202 reacted very strongly. Some reactivity was observed with RYKQKI at 199. MAb 11 reacted in both the three and four amino acid scans with a variety of peptides. However in the five amino acid scan a reaction was obtained with LGSIA at 146 (not shown). In the six amino acid scan ( Fig. 1 ) the reactivity of two peptides stood out: KINSLS at 41 and, much stronger, DLGSIA at 145.
MAb 11 reacted with peptides 41 and 145, MAb 18 with a peptide at the C terminus of VP1 and one starting at 176. The peptides starting at 145 (MAb 11) and at 200 (MAb 18) are within trypsin-sensitive areas of the protein (Strohmaier et al., 1982) . When superimposed on the rhinovirus 14 structure (Rossmann et al., !985) with the aid of an alignment of all amino acid sequences of the picornaviruses (A. Palmenberg, personal communication) peptides 41, 145 and 200 could be located on the viral surface ( Fig. 2 and 3 ), and peptide 176 was found deep inside the protein shell (Fig. 3) . Peptide 41 which reacted with MAb 11 is not indicated in Fig. 2 because we believe that its reactivity was due to similarity with the one starting at 145; when tested in PEPSCANs of seven, eight or nine amino acid peptides, this peptide showed decreasing reactivity in comparison to 145 (not shown).
Antigenicity of peptides
The major reactive peptides were studied in more detail (i.e. LVRMKR/VRMKRA, QKIIAP of MAb 18; KINSLS and DLGSIA of MAb 11). In the areas where reactivity occurred we compared the ELISA absorbance of each three amino acid long peptide with the two four amino acid long peptides that contained the tripeptide. If the addition of an amino acid on either side of the tripeptide resulted in a significant increase of reactivity, the added amino acid was R. H. MELOEN AND OTHERS 2 I 4 2-5 nm Fig. 2 . Schematic representation of the peptides of MAb 18 and MAb l 1 involved in the epitopes, superimposed on a protomer of rhinovirus 14. The location of one of the 60 identical protomers is shown on the virion (icosahedron) as a dotted triangle. The protomer was constructed with the aid of the Calpha backbones of VP1, VP2 and VP3 and is viewed from the outside. The fivefold axis is at the top. The approximate outline of the three structural proteins is shown at the left. In the same diagram the Calpha backbones of the peptides affected by trypsin (Strohmaier et al., 1982) are shown (the numbers indicate the N-and C-terminal amino acid positions of the two peptides on VP 1). In the diagram at the right the C-alpha backbones of the reactive peptides are indicated. The bar indicates the generally assumed approximate diameter of the antibody combining site.
ca)
_" -" regarded as contributing to the binding. Similarly the relevant absorbance values of the four and five amino acid peptides, and the five and six residue peptides were compared. The more often an amino acid contributed to the binding, the higher it scored (Fig. 4) . The results for MAb 18 showed that in LVRMKRA the V at 176 and the second R at 180 were clearly important, and the first R at 177 seemed to contribute as well. takes into account the size and polarity of the side chain and is derived from the circle arrangement described by Doolittle (1985) which places amino acids that have similar properties near one another. For practical reasons we have 'cut' the circle between T and S, and this places some amino acids with similar properties (i.e. small side chains) at the left and right hand sides. The parental sequences are indicated.
and AP at 206 contributed to antibody binding with the emphasis on Q and P. This area contains the largest number of contributing amino acid found so far. In KINSLS and DLGSIA (MAb 11) the contributing amino acids appeared to be separated by three of four non-contributing ones.
Epitope fine structure was further studied with the aid of amino acid replacements (Geysen et al., 1984 (Geysen et al., , 1985 in the two sequences reacting with MAb 18, VRMKRA and YKQKIIAP.
Sometimes the base sequence used was longer than six amino acids if additional amino acids near the reactive peptide appeared to be involved as well. All peptides were produced in which each amino acid at a given position of the original sequence was replaced one at a time by each of 19 other amino acids. For VRMKRA this resulted in a set of 120 peptides (replacement set) and for YKQKIIAP in a set of 160 peptides. These peptides were tested for binding with MAb 18 (Fig. 5) . Concentration of competing antigen (logt0 fmol/ml) Fig. 6 . Results of competition experiments with (a) MAb 18 and (b) MAb 11, peptides and whole virus. Virus was bound to the wells of microtitre plates. A constant amount of antibody (MAb 18 diluted 1/5 x 10 5 or MAb 11 diluted 1/10 s) was added. As competing antigens, peptides or free virus were used as indicated.
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From these results it was clear that VR and the second R of VRMKRA were almost or completely irreplaceable. The same applied for Q, second K, first I and P and to a lesser extent A in YKQKIIAP. These results are similar to those obtained by comparing the different length PEPSCANs (Fig. 4) with the exception of Y at 200 which appeared to contribute somewhat to antibody binding but could be replaced. With MAb 11 the replacement set results (Fig. 5 ) differed much more from those of the different length scans. Whereas in SGDLGSIA D, L and the C-terminal A seemed to contribute to antibody binding (Fig. 4) , the amino acids shown to be crucial by the replacement set approach were the first G, L, second S, I and the C-terminal A (Fig. 5) . This difference was even more apparent with KINSLS. Whereas K and the second S appeared to contribute to binding, both I and L were irreplaceable. The replacement set results with KINSLS are similar to those with SGDLGSIA when the two sequences are aligned as in Fig. 5 .
To assess the extent to which antigenicity of the peptides resembled that of the viral epitopes, the peptides were produced in bulk and their ability to compete with viral antigens for antibody was tested. In general more than one peptide was produced for each reactive site in the sequence. Peptides for the same reactive site were produced with different lengths or starting at different amino acids (see Table 2 ). C or K were added to facilitate linkage to the carrier protein; when they were not part of the sequence they are put within parentheses. The results are shown in Fig.  6 . They indicate that YKQKIIAP competed almost as effectively as intact virus. LVRMKRA(C) also showed competition but surprisingly VRMKRA(C) did not. The peptides reactive with MAb 11, KINSLS(C) and DLGSIAA(C), did not compete; however an analogue of DLGSIAA(C) in which D was replaced by T and I by L did show some competition (not shown).
Immunogenicity of peptides
Finally the immunogenicity of some of these peptides was assessed in animal experiments. The results (Table 2) show that YKQKIIAP was not immunogenic in contrast to a longer version, (C)YKQKIIAP, which was able to induce an antiviral response (ELISA) after a single injection. A still longer version (C)RYKQKIIAPAKQ (based on seven, eight and nine amino acid oligopeptide scans; unpublished results) produced both antiviral and neutralizing activity under the same circumstances, independent of the way it had been coupled to the carrier protein. 2/2 0.9-1.8 2/2 >4.1 ND * Peptide used in ELISA was also used to raise the anti-peptide serum. t C or K was added to the peptide for coupling (by GDA or MBS) to KLH; these residues are given in parentheses when they are not part of the sequence.
:~ In MNT, result was <0.3 and considered negative; in ELISA, result was <2.0. § ND, Not done.
However in competition assays the three peptides were virtually indistinguishable from each other and from viral antigen (W. C. Puyk et al., unpublished results) . LVRMKRA(C) was slightly immunogenic. On the other hand DLGSIAA(C) and GDLGSIA(K) which did not compete with viral antigen were able to induce neutralizing activity after a single injection. However, none of our peptides was as potent in animals as the peptide corresponding to positions 141 to 160 of VP1 of FMDV type O1 (Pfaff et al., 1982; Bittle et al., 1982) , which we used as a control.
DISCUSSION
Because of the conservation of structures within the picornavirus family (Rossmann et al., 1985; Houghten et al., 1985) it is assumed that superposition of FMDV sequences on those of rhinovirus 14, with the aid of the alignment of all amino acid sequences of the structural proteins of picornaviruses (A. Palmenberg, personal communication) is valid. Large deviations from the real situation are not expected. The reactive peptides were found in superficial locations, i.e. starting at amino acids 41, 145 and 200. Because two of these areas (140 to 150 and 200 to 210) are affected when the virus is treated with trypsin (Strohmaier et al., 1982) and since we believe (see below) that peptide 41 recognized by MAb 11 reacts due to its resemblance to peptide 145, peptide 41 is not considered to be part of the MAbl 1 epitope. The trypsin sensitivity of areas 140 to 150 and 200 to 210 further explains why MAbs 11 and 18 do not react with trypsin-treated virus ( Fig. 2 and Table 1 ).
The ability of MAb 18 to react with denatured VP1 (Table l) is consistent with the location of the reactive peptide at the C terminus. This part of VP 1 is located on the virus surface in a more or less linear conformation. In contrast the reactive peptide of MAb I1 (located at starting position 145) is poorly, if at all, expressed by denatured VPI (Meloen & Barteling, 1986b) .
[Interestingly, the ability of the C-terminally located epitopes to withstand denaturation does not seem to be unique to FMDV (Palfreyman et al., 1984) .] However a peptide reacting with MAb 18 and starting at 176 is clearly hidden within the protein shell of the intact virus and cannot be reached by antibody. Since reactive peptides located within the protein shell are often observed, we studied this in more detail.
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MAb 18 reacts strongly with QKIIAP (at 202) and VRMKRA (at 176). QKIIAP or YKQKIIAP (Fig. 2, 3) is exposed on the virus, unlike VRMKRA which is hidden in the virion (Fig. 3) . This cancels out the latter peptide as a candidate for a second part of a presumably discontinuous epitope. The activity of VRMKRA can hardly be explained by chance similarities with YKQKIIAP, as the replacement set patterns and the results of the three, four, five and six amino acid long PEPSCANs (Fig. 4, 5) show that the peptides have their respective essential amino acids at different positions and tolerate replacements that are very different as well. A peptide analogue of VRMKRA which reacts well is PRMKRA (Fig. 5) . One explanation could be that the C terminus of VP3, having the sequence PRTQ which in the virion is located next to YKQKIIAP, is the second part of this epitope. However, alternative explanations cannot be ruled out. For instance V at 194 is due to the conformation located next to R at 199. The antibody could easily 'read' VRYKQKI1AP. These alternatives are being studied currently. Both peptides reactive with MAb 11 are located on the surface in each other's vicinity and one of them, DLGSIA, has been identified as the possible active centre of the much longer immunogenic peptide 141 to 160 described by others (Pfaff et al., 1982; Bittle et aL, 1982; Meloen & Barteling 1986a) . From the replacement set results it appears that when K of KINSLS is lined up with D from GDLGSIA the replacements allowed for each amino acid of KINSLS are similar to those of the relevant amino acids of DLGSIA (Fig. 5) . Also, the contributing amino acids of both peptides suggest similar recognition (Fig. 4) . Thus while GDLGSIA is part or the whole epitope for MAb 11, it seems that KINSLS reacts with this antibody due to the chance resemblance of some of its amino acids at corresponding positions. A similar mechanism might explain why MAbs are often observed that react with numerous peptides.
All four peptides reactive with MAbs 11 or 18, or slightly longer versions, were produced in bulk and their antigenicities were compared with those of viral antigens in competition experiments (Fig. 6) . YKQKIIAP (MAb 18) was virtually indistinguishable from the viral epitope (assuming that viral epitope concentration is the virus concentration x 60; 60 being the number of VP1 s present on one virus particle), while LVRMKRA(C)competed less efficiently. VRMKRA(C) surprisingly did not compete at all. The peptides reacting with MAb 11, i.e. KINSLS(C), DLGSIAA(C) and GDLGSIA(K), did not compete however an analogue, GTLGSLA(K) derived in a systematic fashion from GDLGSIA, did produce some competition (result not shown). Since YKQKIIAP carries more (i.e. six) contributing amino acids than any other peptide tested (Fig. 4) and is also the most antigenic in competition tests (Fig. 6) , it is tempting to speculate that the number of such amino acids is related to the degree of antigenicity of peptides. Not all contributing amino acids are irreplaceable, for instance Y of YKQKIIAP appears to add orders of magnitude to the peptide's ability to compete with viral antigen (W.C. Puyk et al., unpublished) but is replaceable by other amino acids. Using MAb 11 the reverse is found also, i.e. irreplaceable amino acids that do not contribute to binding. While the first observation is not unexpected, the second is less easily understood unless it reflects a structural requirement that can be met only by a particular amino acid that does not directly contribute to antibody binding. If the assumption is correct that the number of contributing amino acids of a peptide is related to its antigenicity, this might explain why peptides unrelated to the epitope of a given MAb may still react with this antibody: two or three similar or identical amino acids properly spaced could make peptides sufficiently antigenic to be recognized by antibody (the other amino acids present being less critical), due to the high sensitivity of the assay system.
That not everyone is aware of this possibility is shown for instance by Diamond et al. (1985) who reported a MAb against poliovirus type 1 that is able to select mutants changed around positions 221 to 223 of VP1 while reacting with a peptide at positions 70 to 80 of the same protein. The mutated area is located at the most exposed part of the virus, in contrast to the peptide which is buried far away from this site deep inside the protein shell (Rossmann et al., 1985; Hogle et al., 1985) , very similar to peptide VRMKRA of FMDV which reacts with MAb 18. Diamond et al. (1985) explained these conflicting results by proposing a complicated neutralization mechanism. Our results, however, may offer a much simpler explanation: peptide 70 to 80 has by chance a few (two or three) appropriately spaced amino acids similar to the original but unknown epitope which is located near the mutation site around positions 221 to Parry et al. (1985) 223. This is consistent with the low antigenicity of this peptide (Emini et al., 1983) . Such fortuitously reacting peptides, which appear to occur often when MAbs are used, could therefore easily lead to wrong conclusions being drawn about the identity and location of epitopes.
Good antigenicity (ability to react with antibody in vitro) does not necessarily always relate to good immunogenicity (ability to induce antiviral activity). This is illustrated by YKQKIIAP which carries six contributing amino acids, is antigenically indistinguishable from the viral epitope, but did not induce any antiviral activity when injected into rabbits in contrast to the longer versions (Table 2 ). The lack of immunogenicity of YKQKIIAP could be due to either the way it is presented to (or recognized by) the immune system, or its conformation [which appears to be different from that in situ in the virus (M. G. Rossmann et al., and W. Gibbons et al., personal communication) ] or its lack of additional amino acids.
If we assume that a peptide can attain optimal immunogenicity only if it has optimal antigenicity to start with, then there is still scope for improvement of the immunogenicity of peptide vaccines. GDLGSIA(K) or DLGSIAA(C) which carry three or four featured amino acids are only poorly antigenic; however, they are able to induce neutralizing activity (Table 2) . Parry et al. (1985) described a 34 amino acid long peptide of VP 1 of FMDV (141 to 160 coupled to 200 to 213) of VP 1 that is thought to represent the whole of a neutralizing epitope. From their competition data with monoclonal antibodies it appears that this peptide is however still 100-fold less antigenic than YKQKIIAP (Table 3) , which suggests that it still lacks sufficient contributing amino acids and may represent only part of a larger epitope. Nonetheless the 141 to 160 part of this peptide (which is even less antigenic in competition than the larger version) is still one of the most immunogenic peptides that has been described (Pfaff et al., 1982; Bittle et al., 1982) .
We speculate that if immunogenicity increases in proportion to antigenicity the efficacy of such peptides can still be raised by orders of magnitude if one is able to improve (systematically) their antigenicity and to apply the peptides in the proper conformation in vaccines.
